FDA Grants Breakthrough Therapy Designation to HERNEXEOS® for First-Line Treatment of HER2-Mutant Advanced NSCLC
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for HERNEXEOS®...
